PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH to Webcast Presentation at the Cowen and Company 38th Annual Healthcare Conference
LYON, France --(BUSINESS WIRE)--Mar. 13, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017
Conference call and webcast on Tuesday, March 13 th at 1:30 pm CET / 8:30 am EDT Reported positive data from Phase 2b clinical trial of eryaspase in second-line metastatic pancreatic cancer Resubmitted the European Marketing Authorization Application (MAA) for eryaspase (GRASPA ® ) in relapsed and
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017
ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017 Conference call and webcast on Tuesday, March 13 th at 1:30 pm CET / 8:30 am EDT Reported positive data from Phase 2b clinical trial of eryaspase in second-line metastatic pancreatic cancer Resubmitted the European
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017
Conference call and webcast on Tuesday, March 13 th at 1:30 pm CET / 8:30 am EDT Reported positive data from Phase 2b clinical trial of eryaspase in second-line metastatic pancreatic cancer Resubmitted the European Marketing Authorization Application (MAA) for eryaspase (GRASPA ® ) in relapsed and
View HTML
Toggle Summary ERYTECH : Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –February 28, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Mar. 7, 2018-- Regulatory News : ERYTECH (Euronext: ERYP- Nasdaq: ERYP) Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq
View HTML
Toggle Summary ERYTECH : Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –February 28, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Mar. 7, 2018-- Regulatory News : ERYTECH (Euronext: ERYP- Nasdaq: ERYP) Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq
View HTML
Toggle Summary ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update
LYON, France --(BUSINESS WIRE)--Mar. 6, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its
View HTML
Toggle Summary ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update
LYON, France --(BUSINESS WIRE)--Mar. 6, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its
View HTML
Toggle Summary ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase
Set-up activities for Phase 2 clinical study ongoing and patient enrollment expected to start Q3 2018 LYON, France --(BUSINESS WIRE)--Feb. 13, 2018-- Regulatory News : ERYTECH Pharma (Euronext: ERYP- Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
Toggle Summary ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase
ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase Set-up activities for Phase 2 clinical study ongoing and patient enrollment expected to start Q3 2018 LYON, France - February 13, 2018 - ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage
View HTML
Top